PVCT Provectus Biopharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. OTC: PVCT

Price (delayed)

$0.19

Market cap

$40.44M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.14

Enterprise value

$35.55M

Sector: Healthcare
Industry: Biotechnology
Website: http://www.provectusbio.com/
Peers: XNCR HALO

Key stats

What are the main financial stats of PVCT
Market
Shares outstanding
212.83M
Market cap
$40.44M
Enterprise value
$35.55M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.42
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$28.98M
EBITDA
-$28.97M
Free cash flow
-$22.12M
Per share
EPS
-$0.14
Free cash flow per share
-$0.1
Book value per share
$0.04
Revenue per share
$0
TBVPS
$0.04
Balance sheet
Total assets
$10.83M
Total liabilities
$1.69M
Debt
$0
Equity
$9.14M
Working capital
$3.72M
Liquidity
Debt to equity
0
Current ratio
3.2
Quick ratio
4.64
Net debt/EBITDA
0.17
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-156.9%
Return on equity
-180.7%
Return on invested capital
-2,255%
Return on capital employed
-317.1%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PVCT stock price

How has the Provectus Biopharmaceuticals stock price performed over time
Intraday
0%
1 week
-5%
1 month
8.82%
1 year
46.15%
YTD
97.92%
QTD
3.88%

Financial performance

How have Provectus Biopharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$28.99M
Net income
-$28.98M
Gross margin
N/A
Net margin
N/A

Growth

What is Provectus Biopharmaceuticals's growth rate over time

Valuation

What is Provectus Biopharmaceuticals stock price valuation
P/E
N/A
P/B
4.42
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A

Efficiency

How efficient is Provectus Biopharmaceuticals business performance

Dividends

What is PVCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PVCT.

Financial health

How did Provectus Biopharmaceuticals financials performed over time
The debt is 100% smaller than the equity

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.